Health Canada Issues Warning Concerning HBV Reactivation with Fatal Outcome OTTAWA, Ontario, Canada — According to Health Canada, the agency in charge of ensuring the safety of medicines marketed in Canada in the same manner that the Food and Drug Administration does in the U.S., issued an alert on March 25, 2019 warning … [Read more...] about Darzalex Hepatitis B Virus Reactivation Death

DARALEX Suspected of Causing Hepatitis B Virus Reactivation in Cancer Patients with Fatal Outcome OTTAWA, Ontario, Canada — Health Canada warns cancer patients suffering from multiple myeloma are at an elevated risk of Hepatitis B virus reactivation while taking the anti-cancer drug DARZALEX. Janssen, Inc., the company that … [Read more...] about Fatal Darzalex Hepatitis B Virus Reactivation Complications